Daunorubicin-induced variations in gene transcription: Commitment to proliferation arrest, senescence and apoptosis

Biochemical Journal

Volumn 372, Issue 3, 2003, Pages 703-711

  Mansilla, Sylvia ^a   Piña, Benjamin ^a   Portugal, José ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

Anthracycline; Array; Cell cycle; Jurkat T lymphocyte; Transcriptome

Indexed keywords

ANTIBIOTICS; CELLS; DNA; MICROSCOPIC EXAMINATION; ONCOGENIC VIRUSES; TUMORS;

GENE TRANSCRIPTION;

GENETIC ENGINEERING;

ANTINEOPLASTIC ANTIBIOTIC; COMPLEMENTARY DNA; DAUNORUBICIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL AGING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; LEUKEMIA CELL LINE; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL AGING; DAUNORUBICIN; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 0037591689     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20021950     Document Type: Article

References (46)

1. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (Cambridge, Mass.) 74, 967-967
2. Brown, J. M. and Wouters, B. G. (1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391-1399
3. Gewirtz, D. A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741
4. Lemon, B. and Tjian, R. (2000) Orchestrated response: a symphony of transcription factors for gene control. Genes Dev. 14, 2551-2569
5. Orphanides, G. and Reinberg, D. (2002) A unified theory of gene expression. Cell (Cambridge, Mass.) 108, 439-451
6. Pinkel, D. (2000) Cancer cells, chemotherapy and gene clusters. Nat. Genet. 24, 208-209
7. Chabner, B. A. and Longo, D. L. (eds.) (2001) Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott-Williams & Wilkins, Philadelphia, PA
8. Gottesfeld, J. M., Turner, J. M. and Dervan, P. B. (2000) Chemical approaches to control gene expression. Gene Expr. 9, 77-91
9. Portugal, J., Martín, B., Vaquero, A., Ferrer, N., Villamarín, S. and Priebe, W. (2001) Analysis of the effects of daunorubicin and WP631 on transcription. Curr. Med. Chem. 8, 1-8
10. Hurley, L. H. (2002) DNA and its associated processes as targets for cancer therapy. Nature Rev. Cancer 2, 188-200
11. Weller, M. (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292, 435-445
12. Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A. G., Bittner, M. L., Meltzer, P. S., Trent, J. M., Dalton, W. S. and Chin, K. V. (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166
13. Brown, J. M. and Wouters, B. G. (2001) Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist. Update 4, 135-136
14. Roninson, I. B. (2002) Tumor senescence as a determinant of drug response in vivo. Drug Resist. Update 5, 204-208
15. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T. et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244
16. Vogelstein, B., Lane, D. and Levine, A. J. (2000) Surfing the p53 network. Nature (London) 408, 307-310
17. Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002) Apoptosis. A link between cancer genetics and chemotherapy. Cell (Cambiidge, Mass.) 108, 153-164
18. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W. and Vogelstein, B. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501
19. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Grant, S., Bullock, G., Huang, Y., Ponnathpur, V. and Mahoney, M. E. (1993) High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82, 3133-3140
20. Han, J. W., Dionne, C. A., Kedersha, N. L., and Goldmacher, V. S. (1997) p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res. 57, 176-182
21. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H. and Levine, A. J. (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993
22. Villamarín, S., Ferrer-Miralles, N., Mansilla, S., Priebe, W. and Portugal, J. (2002) Induction of G2/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T cells. Biochem. Pharmacol. 63, 1251-1258
23. Lotem, J. and Sachs, L. (1996) Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 10, 925-931
24. Chaires, J. B., Fox, K. R., Herrera, J. E., Britt, M. and Waring, M. J. (1987) Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry 26, 8227-8236
25. Binaschi, M., Capranico, G., Dal Bo, L. and Zunino, F. (1997) Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol. 51, 1053-1059
26. White, E. (1996) Life, death, and the pursuit of apoptosis. Genes Dev. 10, 1-15
27. Villamarín, S., Mansilla, S., Ferrer-Miralles, N., Priebe, W. and Portugal, J. (2003) A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur. J. Biochem. 270, 764-770
28. Doyle, A., Griffiths, J. B. and Newell, D. G. (1996) Cell Tissue Culture: Laboratory Procedures, John Wiley & Sons, New York
29. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutelingsperger, C. (1996) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39-51
30. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O. et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 9363-9367
31. 2 response of normal human fibroblasts. Biochem. J. 347, 543-551
32. Bernstein, C. Bernstein, H., Payne, C. M. and Garewal, H. (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 511, 145-178
33. King, K. L. and Cidlowski, J. A. (1998) Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60, 601-617
34. Chen, X., Ko, L. J., Jayaraman, L. and Prives, C. (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451
35. Montaudon, D., Pourquier, P., Denois, F., de Tinguy-Moreaud, E., Lagarde, P. and Robert, J. (1997) Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Eur. J. Biochem. 245, 307-315
36. Chang, B. D., Broude, E. V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E. Sr., Lausch, E., Christov, K. and Roninson, I. B. (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59, 3761-3767
37. Skladanowski, A. and Konopa, J. (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46, 375-382
38. Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J. and Lowe, S. W. (2002) Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22, 3497-3508
39. INK4a contributes to the outcome of cancer therapy. Cell (Cambridge, Mass.) 109, 335-346
40. Seluanov, A., Gorbunova, V., Falcovitz, A., Sigal, A., Milyavsky, M., Zurer, I., Shohat, G., Goldfinger, N. and Rotter, V. (2001) Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol. Cell. Biol. 21, 1552-1564
41. Martinez, L. A., Yang, J., Vazquez, E. S., Rodriguez-Vargas, M. C., Olive, M., Hsieh, J. T., Logothetis, C. J. and Navone, N. M. (2002) p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23, 1289-1296
42. Laurent, G. and Jaffrézou, J. P. (2001) Signaling pathways activated by daunorubicin. Blood 98, 913-924
43. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z. and Kolesnick, R. (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell (Cambridge, Mass.) 82, 405-414
44. Elmore, L. W., Rehder, C. W., Di, X., McChesney, P. A., Jackson-Cook, C. K., Gewirtz, D. A. and Holt, S. E. (2002) Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 277, 35509-35515
45. Capranico, G., Kohn, K. W. and Pommier, Y. (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18, 6611-6619
46. Marín, S., Mansilla, S., Garcia-Reyero, N., Rojas, M., Portugal, J. and Piña, B. (2002) Promoter-specific inhibition of transcription by daunorubicin in Saccharomyces cerevisiae. Biochem. J. 368, 131-136